Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM-PAH
2026-525265-48-00Phase 3Authorised
- Sponsor
- Insmed Incorporated
- Start
- Sep 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Treprostinil palmitil inhalation powder with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance at Week 24. Planned start Sep 2026; status: authorised.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2026-525265-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525265-48-00.